Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

Mammalian cell cultures for biologics manufacturing.

Kantardjieff A, Zhou W.

Adv Biochem Eng Biotechnol. 2014;139:1-9. doi: 10.1007/10_2013_255.

PMID:
24258145
2.

Mammalian cell culture capacity for biopharmaceutical manufacturing.

Ecker DM, Ransohoff TC.

Adv Biochem Eng Biotechnol. 2014;139:185-225. doi: 10.1007/10_2013_215.

PMID:
23748352
3.

Biotech drug market steadily expands.

Lawrence S.

Nat Biotechnol. 2005 Dec;23(12):1466. No abstract available.

PMID:
16333279
4.

'Biosimilar' drugs poised to penetrate market.

Ledford H.

Nature. 2010 Nov 4;468(7320):18-9. doi: 10.1038/468018a. No abstract available.

PMID:
21048737
5.
6.

The challenge of follow-on biologics for treatment of multiple sclerosis.

Reingold SC, Steiner JP, Polman CH, Cohen JA, Freedman MS, Kappos L, Thompson AJ, Wolinsky JS.

Neurology. 2009 Aug 18;73(7):552-9. doi: 10.1212/WNL.0b013e3181b2a6ce. Review.

PMID:
19687456
7.

Market exclusivity for biologics.

Wheadon DE.

N Engl J Med. 2010 Feb 18;362(7):661; author reply 661-2. doi: 10.1056/NEJMc0912463. No abstract available.

8.

The biotech drug market.

Lawrence S.

Nat Biotechnol. 2004 Dec;22(12):1496. No abstract available.

PMID:
15583645
9.

Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.

DiMasi JA.

Clin Ther. 2013 Jun;35(6):808-18. doi: 10.1016/j.clinthera.2013.04.004. Epub 2013 May 28.

PMID:
23726388
10.

Recombinant protein therapeutics--success rates, market trends and values to 2010.

Pavlou AK, Reichert JM.

Nat Biotechnol. 2004 Dec;22(12):1513-9. No abstract available.

PMID:
15583654
11.

Security market reaction to FDA fast track designations.

Anderson CW, Zhang Y.

J Health Care Finance. 2010 Winter;37(2):27-48.

PMID:
21294437
12.

2004 approvals: the demise of the blockbuster?

Frantz S.

Nat Rev Drug Discov. 2005 Feb;4(2):93-4. No abstract available.

PMID:
15756752
13.

3 New Biologics To Be Worth $14B in Sales by 2019.

Adams KT.

Manag Care. 2015 May;24(5):36-7. No abstract available.

14.

Safety assurance for biologics manufactured in mammalian cell cultures: a multitiered strategy.

Chen D.

Adv Biochem Eng Biotechnol. 2014;139:167-83. doi: 10.1007/10_2013_213.

PMID:
23719711
15.

Biopharmaceutical benchmarks 2010.

Walsh G.

Nat Biotechnol. 2010 Sep;28(9):917-24. doi: 10.1038/nbt0910-917. No abstract available.

PMID:
20829826
16.

Satisfaction guaranteed--"payment by results" for biologic agents.

Garber AM, McClellan MB.

N Engl J Med. 2007 Oct 18;357(16):1575-7. No abstract available.

PMID:
17942870
17.

Market uptake of biologic and small-molecule--targeted oncology drugs in Europe.

Obradovic M, Mrhar A, Kos M.

Clin Ther. 2009 Dec;31(12):2940-52. doi: 10.1016/j.clinthera.2009.12.019.

PMID:
20110034
18.

Hybrid and disposable facilities for manufacturing of biopharmaceuticals: pros and cons.

Ravisé A, Cameau E, De Abreu G, Pralong A.

Adv Biochem Eng Biotechnol. 2009;115:185-219. doi: 10.1007/10_2008_24. Review.

PMID:
19623478
19.

Market watch: Sales of biologics to show robust growth through to 2013.

Goodman M.

Nat Rev Drug Discov. 2009 Nov;8(11):837. doi: 10.1038/nrd3040. No abstract available.

PMID:
19876035
20.

Supplemental Content

Support Center